Last reviewed · How we verify

NCT02528006

Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges

Completed Phase 2, PHASE3 Last updated 2 May 2018
What this trial tests

Phase 2, PHASE3 trial testing Type 2 Thyroplasty using Titanium Bridges in Adductor Spasmodic Dysphonia in 20 participants. Completed in 29 March 2017.

Timeline
27 July 2015
Primary endpoint
29 March 2017
29 March 2017

Quick facts

Lead sponsorKumamoto University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment20
Start date27 July 2015
Primary completion29 March 2017
Estimated completion29 March 2017
Sites4 locations across Japan

Drugs / interventions tested

Conditions studied

Sponsor

Kumamoto University

Who can join

Adults 18 to 80, any sex, with Adductor Spasmodic Dysphonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For adductor spasmodic dysphonia, there is a need for establishing a new therapy under the present circumstance where no standard therapy has been established yet and existing therapies fail to provide permanent effect. Evaluation of the efficacy of type 2 thyroplasty using titanium bridges will expand the therapeutic options available for adductor spasmodic dysphonia and establishment of a standard therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Kumamoto University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02528006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing